Inhibrx Biosciences Incの企業情報（従業員数・代表者名など）
企業情報
| 特色 | Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while |
|---|---|
| 英文社名 | Inhibrx Biosciences Inc |
| 本社所在地 | 11025 N. Torrey Pines Road, Su LA JOLLA, CA 92037 USA |
| 電話番号 | 858 795-4220 |
| 設立年月 | 2024年1月 |
| 代表者名 | --- |
| 業種名 | 医療関連（Health Care） |
| 市場名 | NASDAQ National Market System |
| 従業員数 | --- |
| ウェブサイト | --- |
